Gordon Brothers Retail Partners, 800 Boylston St, Boston, MA 02199, US

Verastem Oncology, based in Boston, MA, is a biopharmaceutical company dedicated to developing innovative treatments for patients with RAS pathway-driven cancers. With a focus on mutations in the RAS family of genes, including KRAS, NRAS, and HRAS, Verastem Oncology aims to provide better options and outcomes for patients through targeted treatment combinations with avutometinib. Their research and development efforts are driven by a commitment to exploring uncharted paths and expanding possibilities for patients with difficult-to-treat cancers. Recognizing the significant impact of RAS pathway mutations on patient outcomes, Verastem Oncology is determined to ensure that no cancer patient runs out of options. By blocking multiple nodes in the RAS pathway, avutometinib, also known as VS-6766, has the potential to become a backbone of therapy when combined with other agents targeting the RAS pathway and parallel pathways involved in tumor growth and metastases. Through their relentless pursuit of innovative treatments, Verastem Oncology aims to provide patients with more choices and the hope of better outcomes.Generated from the website

Oliver Peoples

Alo

Aerotek

Paper Source